For laboratory research use only. This material is not a drug, is not approved by the FDA for any use, and must not be administered to humans or animals.
Volume pricing applies from 2 vials. Free cold-chain shipping on orders over $150.
Scientific Overview
Tirzepatide is a synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Dual-receptor pharmacology is an active area of metabolic research.
Mechanism
Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Dual incretin receptor engagement is studied for downstream effects on metabolic signaling pathways in laboratory research models.
Areas of Active Scientific Research
Researchers continue to investigate Tirzepatide for its potential influence on metabolic regulation, glucose homeostasis, appetite signaling, energy balance, and body composition in laboratory models.
Molecular Characteristics
- Molecular weight
- 4813.5 Da
- Formula
- C225H348N48O68
- Sequence
- 39 amino acid synthetic peptide (GIP/GLP-1 dual agonist scaffold)
- Appearance
- White to off-white lyophilized powder supplied in research vial format.
- Vial size
- 15mg
- Grade
- Research grade (RUO)
Storage Recommendations
For laboratory research use only. Store lyophilized material at −20°C or below. Reconstitute and handle according to institutional SOPs for peptide research.
Purity
Target purity ≥99% by HPLC. The binding value for any vial is the result on that lot’s Certificate of Analysis.
Batch documentation
Contact support with your order or batch number to request the analytical record for a specific lot, or use COA Verification.
support@primelabs.bioWhat a COA demonstrates
Batch-specific identity verification, purity by validated analytical methods (e.g. HPLC), and third-party laboratory testing records for the referenced lot.
What a COA does not demonstrate
Clinical efficacy, safety for human or veterinary use, or suitability for any application outside qualified laboratory research.
Quality Assurance
Each lot is supported by batch-specific analytical documentation used to verify identity and purity. The Certificate of Analysis is the binding record for that vial.
References
Selected peer-reviewed literature for research context. Prime Labs citations do not constitute therapeutic claims.
- Frias J.P. et al. — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
- Jastreboff A.M. et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.